Antiplatelet or anticoagulant therapy might not increase the risk of haemoptysis in patients with bronchiectasis

Int J Tuberc Lung Dis. 2013 Jul;17(7):989-91. doi: 10.5588/ijtld.12.0807. Epub 2013 May 3.

Abstract

The aim of this study was to assess whether the use of antiplatelets and anticoagulants increased haemoptysis in patients with bronchiectasis. Cases (n = 242) with a history of haemoptysis were compared with controls (n = 242) without a history of haemoptysis. Of the 242 case patients, 16.5% took antiplatelets compared with 19.8% of controls (P = 0.346). The proportion of warfarin users did not differ between cases and controls (3.3% vs. 2.5%, P = 0.588). The use of these agents might not be associated with increased risk of haemoptysis in patients with bronchiectasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects*
  • Bronchiectasis / complications*
  • Bronchiectasis / physiopathology
  • Case-Control Studies
  • Female
  • Hemoptysis / epidemiology
  • Hemoptysis / etiology*
  • Humans
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / adverse effects*
  • Warfarin / administration & dosage
  • Warfarin / adverse effects

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors
  • Warfarin